Features of Use of Combined Glow-Lowing Therapy in Patients with Type 2 Diabetes and IHD

Simple item page
dc.creatorSobirdjanovna, Kurbanova Nozima
dc.creatorYusufbek, Jo’raboyev
dc.creatorSuhrob, Omonov
dc.creatorJamshid, Orziyev
dc.creatorDilorom, Omonova
dc.date2024-04-22
dc.date.accessioned2024-10-12T12:36:05Z
dc.date.available2024-10-12T12:36:05Z
dc.descriptionRelevance. Diabetes mellitus (DM) is a serious medical and social problem in all countries and at all ages. The combination of type 2 diabetes (T2DM) and coronary heart disease (CHD), according to some data, is 70–80% in patients with diabetes mellitus. Poor glycemic control is the most significant risk factor for the development of cardiovascular complications, which has been confirmed in various basic studies. One of the socially significant diseases is type 2 diabetes mellitus (T2DM). Large clinical studies have shown that diabetes mellitus increases the risk of developing CVD: coronary heart disease (including myocardial infarction), cerebral ischemic stroke, atherosclerosis of the great vessels, thrombosis of arteries and veins, chronic heart failure and worsens the prognosis for these pathologies. Myocardial contractility is a basic characteristic of the pumping function of the heart, and its determination in pathology is of considerable interest. The literature has repeatedly described a decrease in myocardial contractile activity against the background of T2DM, however, recent in vivo studies on ischemic myocardium of an experimental model cast doubt on the irrefutability of this statement. Recent years have been characterized by a steady increase in the number of patients with type 2 diabetes mellitus (DM). According to experts from the International Diabetes Association (IDF), by 2035 the number of people with diabetes in the world will reach 592 million people, which is almost every tenth inhabitant of the planet [29]. In the Russian Federation, according to the State Register as of January 1, 2015, the number of patients with diabetes amounted to 4.094 million people [4]. Type 2 diabetes is characterized by a high risk of developing coronary heart disease (CHD), myocardial infarction, stroke, heart failure, and it is also known that diabetes and cardiovascular diseases (CVD) mutually aggravate each other. In type 2 diabetes, the risk of developing coronary artery disease increases 2–5 times [45]. Numerous studies show that more than half of patients are unaware of the presence of type 2 diabetes, and diagnosis often occurs against the background of existing cardiovascular complications [9, 49]. Almost 50% of patients with an established diagnosis of coronary artery disease are diagnosed with newly diagnosed type 2 diabetes, impaired glucose tolerance, or fasting hyperglycemia [9]. In this regard, the American Heart Association (AHA) has defined the presence of type 2 diabetes patients as equivalent to a high risk of vascular complications, comparable to that of overt CVD [22]. Against the background of the prevalence of type 2 diabetes, there is a high mortality rate and early disability in patients of working age. Thus, more than 50% of diabetes-related mortality is mediated by cardiovascular pathology [4]. Mortality among patients with type 2 diabetes from CVD is 3–4 times higher than similar rates in the general population. In developed countries, where significant progress has been made in the fight against coronary heart disease, it was noted that patients with diabetes are the only group in which mortality from this disease decreased slightly in men and increased in women [17]. Patients with type 2 diabetes are characterized by a high incidence of “painless” myocardial infarction and sudden cardiovascular death. The presence of a blurred clinical picture leads to late diagnosis of the disease, often already at the stage of severe complications in the form of sudden death or blood supply failure [11]. The high mortality rate of patients with diabetes is associated with systemic atherosclerotic lesions of the vascular bed. Mixed or isolated dyslipidemia (increased levels of triglycerides and/or serum cholesterol) is usually determined in every second elderly patient with type 2 diabetes [13]. In diabetes in the pathogenesis of atherosclerosis, well-studied risk factors are distinguished, including non-correctable (age, gender, heredity) and correctable (arterial hypertension, smoking, unbalanced diet, obesity and physical inactivity), as well as partially correctable (dyslipidemia, insulin resistance, psycho-emotional stress ). Atherosclerotic damage to vessel walls in type 2 diabetes is characterized by earlier development and rapid progression of the process [11, 33]. In its turn,hyperglycemia in diabetes promotes the development of atherogenesis in the vascular wall with a high prevalence of atherosclerotic lesions with endothelial damage, growth of smooth muscle cells, fibrinolysis, thrombus formation, proliferation and increased oxidative stress with the triggering role of cytokines [3].en-US
dc.formatapplication/pdf
dc.identifierhttps://journals.proindex.uz/index.php/JSML/article/view/873
dc.identifier.urihttps://dspace.umsida.ac.id/handle/123456789/37513
dc.languageeng
dc.publisherPro Indexen-US
dc.relationhttps://journals.proindex.uz/index.php/JSML/article/view/873/733
dc.sourceJournal of Science in Medicine and Life; Vol. 2 No. 4 (2024): Journal of Science in Medicine and Life; 40-44en-US
dc.source2992-9202
dc.subjecttype 2 diabetes mellitusen-US
dc.subjectstable coronary heart diseaseen-US
dc.subjectcontinuous glycemic monitoringen-US
dc.subjectheart rate variabilityen-US
dc.titleFeatures of Use of Combined Glow-Lowing Therapy in Patients with Type 2 Diabetes and IHDen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Articleen-US
Files
Collections
Journal of Science in Medicine and Life